Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G G Chabot

Showing results (21-30 of 53) with videos related to

Pageof 6
Sort By:
Leukemia & Lymphoma|July 1, 1995
Main drug-metabolizing enzyme systems in human non-Hodgkin's lymphomas sensitive or resistant to chemotherapyV Ribrag, L Massaad, F Janot, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1989
Pharmacodynamics and causes of dose-dependent pharmacokinetics of flavone-8-acetic acid (LM-975; NSC-347512) in miceG G Chabot, M C Bissery, T H Corbett, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1993
Tumour necrosis factor-alpha plasma levels after flavone acetic acid administration in man and mouseG G Chabot, D Branellec, A Sassi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1995
Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patientsD Abigerges, G G Chabot, J P Armand, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 1, 1993
Test dose-guided administration of cisplatin in an anephric patient: a case reportV Ribrag, J P Droz, J Morizet, et al.
Cancer Research|April 1, 1985
Phase I study and pharmacokinetics of weekly high-dose 13-cis-retinoic acidG Clamon, G G Chabot, F Valeriote, et al.
Archives of Biochemistry and Biophysics|January 1, 1997
Expression and inducibility of cytochrome P450 3A9 (CYP3A9) and other members of the CYP3A subfamily in rat liverA Mahnke, D Strotkamp, P H Roos, et al.
Leukemia Research|November 1, 1994
Principal drug-metabolizing enzyme systems in L1210 leukemia sensitive or resistant to BCNU in vivoV Ribrag, L Massaad, F Janot, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1994
Influence of tumor size on the main drug-metabolizing enzyme systems in mouse colon adenocarcinoma Co38L Massaad, G G Chabot, C Toussaint, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1995
Phase I and pharmacology study of flavone acetic acid administered two or three times weekly without alkalinizationM de Forni, G G Chabot, J P Armand, et al.
Pageof 6

Showing results (21-30 of 53) with videos related to

Sort By:
Pageof 6
Leukemia & Lymphoma|July 1, 1995
Main drug-metabolizing enzyme systems in human non-Hodgkin's lymphomas sensitive or resistant to chemotherapyV Ribrag, L Massaad, F Janot, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1989
Pharmacodynamics and causes of dose-dependent pharmacokinetics of flavone-8-acetic acid (LM-975; NSC-347512) in miceG G Chabot, M C Bissery, T H Corbett, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1993
Tumour necrosis factor-alpha plasma levels after flavone acetic acid administration in man and mouseG G Chabot, D Branellec, A Sassi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1995
Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patientsD Abigerges, G G Chabot, J P Armand, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 1, 1993
Test dose-guided administration of cisplatin in an anephric patient: a case reportV Ribrag, J P Droz, J Morizet, et al.
Cancer Research|April 1, 1985
Phase I study and pharmacokinetics of weekly high-dose 13-cis-retinoic acidG Clamon, G G Chabot, F Valeriote, et al.
Archives of Biochemistry and Biophysics|January 1, 1997
Expression and inducibility of cytochrome P450 3A9 (CYP3A9) and other members of the CYP3A subfamily in rat liverA Mahnke, D Strotkamp, P H Roos, et al.
Leukemia Research|November 1, 1994
Principal drug-metabolizing enzyme systems in L1210 leukemia sensitive or resistant to BCNU in vivoV Ribrag, L Massaad, F Janot, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1994
Influence of tumor size on the main drug-metabolizing enzyme systems in mouse colon adenocarcinoma Co38L Massaad, G G Chabot, C Toussaint, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1995
Phase I and pharmacology study of flavone acetic acid administered two or three times weekly without alkalinizationM de Forni, G G Chabot, J P Armand, et al.
Pageof 6